Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thailand Shows Early Signs Of Resistance To Basic Malaria Drug

This article was originally published in PharmAsia News

Executive Summary

Thailand once again is showing the world a danger of emerging resistance to a major drug, this time the deadliest form of malaria to artemisinin, the basic ingredient in the leading treatments. Researchers for a recently published study have determined the drug is losing potency in Thailand, signaling a global need for a new generation of drugs. The effort to generate a sense of emergency has been hampered by more recent studies that show there have been relatively no signs of the artemisinin resistance. An area on the Thai border with Cambodia has a history as the starting point for resistance to malaria drugs. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts